Purpose Augmented renal clearance (ARC) is common in critically ill patients and may lead
to subtherapeutic levels of antibiotics, thus influencing clinical outcomes and emergence of …

Piperacillin-tazobactam is a potent β-lactam/β-lactamase inhibitor antibiotic commonly
prescribed in the intensive care unit setting. Admitted patients often show large variability in …

Purpose Inadequate piperacillin (PIP) exposure in intensive care unit (ICU) patients
threatens therapeutic success. Model-informed precision dosing (MIPD) might be promising …

Nivolumab and pembrolizumab, anti–programmed cell death protein 1 monoclonal
antibodies, have revolutionized oncology but are expensive. Using an interventional …

Atezolizumab, a humanized monoclonal antibody against programmed cell death ligand 1
(PD‐L1), was initially approved in 2016, around the same time that the sponsor published …

Continuous infusion (CI) piperacillin/tazobactam is frequently used to treat infections in very
elderly patients. This study aimed to conduct a population pharmacokinetic analysis of CI …

Abstract Background and Objectives Although dose optimization studies have been
performed for piperacillin and tazobactam separately, a combined integral analysis is not yet …

Background: The antibacterial effect of antibiotics is linked to the free drug concentration.
This study investigated the applicability of an ultrafiltration method to determine free plasma …

Abstract Purpose of Review In this narrative review encompassing relevant scientific
publications regarding critically ill patients in the last 5 years, we discuss key questions …

Background: The aims of this study were to describe pharmacokinetic/pharmacodynamic
target attainment in intensive care unit (ICU) patients treated with continuously infused ß …